- Company
- Wegovy's release on the 15th…competitor Mounjaro
- by Whang, byung-woo Oct 8, 2024 05:49am
- With the release of Wegovy, the next-generation obesity drug, set for the middle of this month (October), the release of its competitor Mounjaro is also gaining attention. Although Lilly has not yet announced a specific launch date for its Mounjaro, the company has opted to add another indication to its drug rather than apply for new drug app
- Company
- Ilaris can be prescribed at general hospitals in KOR
- by Eo, Yun-Ho Oct 8, 2024 05:49am
- Ilaris, which was listed for reimbursement 9 years after receiving marketing authorization in Korea, can now be prescribed at general hospitals in Korea. According to industry sources, Novartis Korea's hereditary recurrent fever syndrome drug Ilaris (canakinumab) has passed the drug committees (DCs) of Seoul National University Hospital,
- Policy
- Daewoong wins nod for first generic version of Ibrance tab
- by Lee, Tak-Sun Oct 8, 2024 05:49am
- Daewoong's first generic for Pfizer's breast cancer treatment, 'Ibrance Tab,' has been approved. Due to the successful patent nullification, the company received priority marketing authorization. The first generic can be launched in March 23rd, 2027, when the product patent expires. The Ministry of Food and Drug Safety (MFDS) has granted
- Company
- Eisai Korea signs Alzheimer's MOU with the Korean Dementia
- by Whang, byung-woo Oct 8, 2024 05:49am
- Eisai Korea announced on October 7th that it has signed a memorandum of understanding (MOU) with the Korean Dementia Association to utilize and manage 'JOY-ALZ,' a registry program for long-term follow-up survey platform of Alzheimer's disease prognosis. The MOU aims to advance Alzheimer's disease treatment and to establish safe Alzheime
- Company
- Galderma Korea appoints Jai Hyuk Lee as new GM
- by Whang, byung-woo Oct 8, 2024 05:48am
- Galderma Korea announced on the 7th that it has appointed Jake (Jai Hyuck) Lee, former head of the Aesthetics Business Unit, as its new General Manager, effective as of October 1. The new GM is a seasoned sales and marketing expert with more than 25 years of experience in the global pharmaceutical and aesthetics industries. Lee will succe
- Policy
- Drugs for NSCLC harboring MET alterations pass CDRC review
- by Lee, Tak-Sun Oct 7, 2024 05:48am
- A treatment for non-small cell lung cancer (NSCLC) harboring MET alterations has passed the first stage for reimbursement coverage by national health insurance. Merk's Tepmetko is the drug that passed. On October 2nd, the Cancer Disease Review Committee (CDRC) of the Health Insurance Review and Assessment Service (HIRA) commenced the 7th m
- Company
- Yuhan·Dongwha as potential distributor for Bayer's OTC drug
- by Nho, Byung Chul Oct 7, 2024 05:48am
- Bayer seeks a new distributor·seller for its leading over-the-counter (OTC) medications, including 'Canesten·Bepanthen.' According to industry sources, Bayer is searching for a new distributor to distribute its OTC medications, Canesten and Bepanthen, ahead of the termination of its OTC co-promotion agreement with Il Dong Pharmaceutic
- Policy
- 'Qarziba' to be reconsidered for the DREC review in KOR
- by Lee, Tak-Sun Oct 7, 2024 05:48am
- Qarziba (dinutuximab, Recordati Korea), which was designated as the 1st drug for a "Pilot Project for Integration of Product Approvals, Reimbursement Coverage Reviews, and Drug Price Negotiations" will be reconsidered for the Drug Reimbursement Evaluation Committee (DREC) review. Qarziba was considered for the DREC review in August but re
- Opinion
- [Reporter’s View]Contradictions in the CSO reporting system
- by Kim, Jin-Gu Oct 7, 2024 05:48am
- The implementation of the CSO reporting system is now just 2 weeks away. It means that after the 19th of this month, no one will be able to engage in sales and promotion activities in the pharmaceutical industry without a CSO report certificate. Although there are only 2 weeks left until the law takes effect, there is still confusion amo
- Company
- Darzalex seeks reimbursement extensions again in KOR
- by Whang, byung-woo Oct 7, 2024 05:48am
- With Janssen Korea reapplying to extend the reimbursement of its Darzalex (daratumumab), which it first failed at the Drug Reimbursement Evaluation Committee’s stage, whether the company will succeed in making progress in its discussions this time is gaining attention. According to industry sources on the 4th, the Health Insurance Revie
